We're joined today by Dr. Aaron Goodman, a hematologist/oncologist at the University of California San Diego, to talk about calling out an unethical clinical trial, Melflufen, and academic oncology.

We're joined by Dr. Bapu Jena of Harvard Medical School to talk about his show, Freakonomics, M.D., and his career at the intersection of economics and medicine.

We have three topics for you today: We talk about our recent paper on the use of second-line immunotherapy in kidney cancer, the controversy over whether a cancer clinical trial was unethical, and the results of the randomized clinical trial CASSIOPEIA.

Today we have an interview with Dr. Zeb Jamrozik, an infectious disease bioethicist at the Monash Bioethics Centre and the University of Oxford. We talk about COVID-19 health policy and where we went wrong, speaking specifically from the values framework of health, fairness, and freedom.

We have a summary of our thoughts for you on recent news about COVID. We discuss the prospect of FDA authorization of a Moderna booster, 8 lessons for health policy in times of crisis, updates on myocarditis data from Israel and Europe, how our experiences with COVID warn us of the possible end to democracy, how progressivism is dead, why social media should not censor views, the CDC's new masking studies, the slogan "follow the science", weekly testing of vaccinated college students who don't have symptoms, the survival of science after COVID, and the question of requiring a booster to follow the Johnson & Johnson vaccine.

On today's episode we're joined by a number of special guests: Dr. Christopher Booth and Dr. Adam Fundytus of Queen's University in Kingston, Ontario, Dr. Manju Sengar of the Tata Memorial Centre, and Dr. Aaron Goodman of the University of California at San Diego. We talk about their new papers: "Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey", "Practicing on the edge of oncology: when standard of care feels uncomfortable", and "Has the Current Oncology Value Paradigm Forgotten Patients’ Time? Too Little of a Good Thing".

On today's episode, in honor of him and in recognition of his passing, we have an old interview with Dr. Elihu Estey of the University of Washington on his 40 years of experience as an oncologist, the "Renaissance" of drugs for leukemia, and advice for trainees on how to approach career goals. This interview originally aired as episode 1.49. He will be missed.

This week we take a break from #zerocovid to give you another episode that's a deep dive into COVID-19. We start with an interview with epidemiologist and infectious disease expert Dr. Daniel Morgan of the University of Maryland School of Medicine; we talk about cognitive errors in medical decision-making and how it relates to COVID-19 health policy. After that, we have a series of thoughts for you on COVID vaccine mandates for schools, President Biden's vaccine plan, the FDA's vote on boosters, John Ioannidis' new paper on vaccinating students, the Pfizer results for vaccines in kids 5-11, and accepting that COVID is here to stay.

Today we take a brief break from our #zerocovid mantra to offer you our thoughts on current events. We cover a variety of topics, including: medical doctors in academia, cancelling conferences even for the vaccinated, masking 2-year-olds, equipoise, the CDC Georgia study, myocarditis, booster shots, outdoor masking at Duke, no more zero COVID in Australia, the Bangladesh cluster RCT on masks and its implications for kids in the USA, the resignation of two senior FDA officials, LA schools mandating vaccines, vaccinating college students, and more.

Today's episode is a lecture our host, Dr. Vinay Prasad of University of California San Francisco, gave recently on censoring patients in Kaplan-Meier plots.

Today we're joined by social epidemiologist, Dr. Maria Glymour of UCSF. We talk about her work in studying public health interventions for dementia and how her experience in academia has led to her conviction in the necessity of rigorous, quantitative technical skills training for epidemiology PhD students. We touch on how to have a good idea, her advice for PhD applicants, and working in a soft money (grants) vs hard money environment. Finally, we discuss her idea for a stepped-wedge trial approach to evaluate the new Alzheimer's drug, aducanumab.

We have two oncology conversations for you today. The first is with Dr. Saroj Niraula of the University of Manitoba, and together we discuss the necessity of randomized controlled trials for granting FDA approval of cancer drugs. The second is with Dr. Ghulam Rehman "Manni" Mohyuddin of the University of Utah on a variety of myeloma studies, including LIGHTHOUSE, OCEANS, and HORIZON.

Today we interview Dr. Bita Fakhri of UCSF on the current research behind treatments for lymphoma. We touch on CAR-T, ABVD, DA-EPOCH-R, and more. We also talk about histiocytic disorders, Dr. Fakhri's career in academia, and learning through teaching.

Today we interview Dr. Alan Venook of UCSF, a renowned expert in clinical trial design and gastrointestinal malignancies. We talk about the evolution of the treatment for colorectal cancer over the last few decades, starting with 5FU. We also discuss his time working as an editor for the Journal of Clinical Oncology and we talk about his advice for budding clinical trialists.

Today we interview Dr. Josee-Lyne Ethier of Queen's University in Kingston, Ontario, Canada on her new paper "Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer", out now in JAMA Oncology. We talk about the real-world survival outcomes for pertuzumab and T-DM1, comparing these outcomes to the results of pivotal clinical trials CLEOPATRA and EMILIA.

Today we interview Dr. Josee-Lyne Ethier of Queen's University in Kingston, Ontario, Canada on her new paper "Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer", out now in JAMA Oncology. We talk about the real-world survival outcomes for pertuzumab and T-DM1, comparing these outcomes to the results of pivotal clinical trials CLEOPATRA and EMILIA.

Today's episode is a compilation of a few short monologues. We provide an oncologist's evidence-based medicine perspective on four papers: CheckMate 274, adjuvant nivolumab in urothelial cancer; PARADIGM-HF/Entresto; the POLO trial, olaparib in pancreas cancer; and the paper "An algorithmic approach to reducing unexplained pain disparities in underserved populations".

Today we sit down (in person!) with Dr. Jeff Bien of Stanford University to break down all the details -- from the methods to the statistical analysis to the conclusions -- of the CheckMate 649 trial, which pitted first-line nivolumab plus chemotherapy against chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma.

Today we have two short monologues for you on recent papers. The first, by popular request, is the problems with the VISION trial, which treated metastatic castration-resistant prostate cancer with lutetium-177–PSMA-617 (Lu-177–PSMA-617) radioligand therapy and standard of care. The second is on the paper recently published in Science titled "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients".

In today's quick episode, we talk about our new paper out now in JAMA Network Open titled "The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval”